LINFOMAS Y TRASPLANTES
Hospital Vall d'Hebron
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (73)
2024
-
Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)
Transplantation and Cellular Therapy, Vol. 30, Núm. 1, pp. 93.e1-93.e12
-
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 205-217
-
Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy
HemaSphere, Vol. 8, Núm. 5
2023
-
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 430-437
-
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Haematologica, Vol. 108, Núm. 1, pp. 110-121
-
Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)
Bone Marrow Transplantation
-
Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome
British Journal of Haematology, Vol. 200, Núm. 3, pp. 306-314
-
Identifying Early Infections in the Setting of CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
HemaSphere, Vol. 7, Núm. 4, pp. E858
-
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
eClinicalMedicine, Vol. 65
-
Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study
British Journal of Haematology, Vol. 203, Núm. 2, pp. 182-193
-
Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study
BMJ open, Vol. 13, Núm. 7, pp. e071371
-
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era
Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679
-
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL
American Journal of Hematology, Vol. 98, Núm. 11, pp. 1699-1710
2022
-
BCL2 translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival
Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 101-108
-
A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression
Blood Advances, Vol. 6, Núm. 21, pp. 5763-5773
-
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
Haematologica, Vol. 107, Núm. 11, pp. 2675-2684
-
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
Frontiers in Immunology, Vol. 13
-
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia
Nature Medicine, Vol. 28, Núm. 8, pp. 1662-1671
-
Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications
Histopathology, Vol. 81, Núm. 6, pp. 826-840
-
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205